– USA, MA – Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji (R.Ph.) to its Board of Directors.
“We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases,” said CEO, Dr. John Leonard. “We are very fortunate to benefit from Muna’s extensive experience navigating U.S. and global healthcare systems to improve patient access to innovative medicines. We are thrilled with her joining our board and look forward to her many contributions to our future success.”
About Muna Bhanji
Ms. Bhanji brings more than 30 years of strategic and operational experience in the biopharmaceutical industry to Intellia’s board, including a proven track record of driving growth across a broad portfolio of medicines and vaccines. She built her career at Merck & Co., where she held several senior leadership roles within U.S.-based sales, marketing, managed markets and commercial operations, global franchise business units, and global market access and policy. She is the founder and president of Tiba Global Access, a commercialization and market access strategy consultancy serving the biopharmaceutical industry. Ms. Bhanji serves on the board of directors for several companies, including Cytokinetics (NASDAQ: CYTK), Ardelyx, Inc. (NASDAQ: ARDX), and Veracyte, Inc. (NASDAQ: VCYT). She also is a member of the board of Corus International, an international humanitarian organization working at the intersection of poverty alleviation and healthcare.
Ms. Bhanji earned her B.S. in Pharmacy from Rutgers School of Pharmacy and an MBA from St. Joseph’s University.
About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine.
For more information: https://www.intelliatx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
